On February 16, 2016 Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, reported that Daniel J. O’Connor, president and chief executive officer, will present an overview of the company’s business strategy and corporate programs at the 2016 RBC Capital Markets Global Healthcare Conference at the New York Palace in New York City (Press release, Advaxis, FEB 16, 2016, View Source [SID:1234509060]). Advaxis’ presentation will take place on Tuesday, February 23 at 11:30 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will provide an update on the Company’s key milestones and initiatives for 2016 including its soon to be launched Phase 3 trial for axalimogene filolisbac for the treatment of high-risk locally advanced cervical cancer (AIM2CERV) and the launch of a Phase 2 trial in metastatic anal cancer (FAWCETT). The presentation will also review Advaxis’ advancing work in neo-epitopes through its partnership with Memorial Sloan Kettering Cancer Center and ongoing work in prostate cancer and with HER2-driven tumors.